Market Overview
The Panitumumab market is predicted to
develop at a compound annual growth rate (CAGR) of xx from
2024 to 2034, when it is projected to reach USD xx Billion, based on an average
growth pattern. The market is estimated to reach a value of USD xx Billion in
2024.
SOURCE: We Market Research
A monoclonal
antibody called panitumumab targets the epidermal growth factor receptor (EGFR)
and is used to treat metastatic colorectal cancer, particularly in patients
with tumors that are KRAS wild-type. When given intravenously, it prevents the
development of cancer cells by obstructing EGFR signaling pathways. Skin rash
and low magnesium levels are common side effects; severe allergic reactions and
lung problems are examples of major ones. Before starting treatment, KRAS
mutation testing is necessary to guarantee efficacy. Panitumumab is sold under
the Vectibix brand and is frequently used with other chemotherapeutic drugs.
The rise in colorectal cancer cases worldwide, technological developments, and the growing inclination towards targeted therapies over conventional chemotherapy because of their greater effectiveness and reduced side effects are the main factors propelling the panitumumab market. The need for treatments based on genetic profiles is increased by the emphasis on customized medicine. The need for panitumumab is further increased by an aging population that is more susceptible to cancer. The market's reach is increased by regulatory approvals for novel indications and combination medicines, and the overall expansion of the market is bolstered by better access to cutting-edge cancer treatments in emerging economies thanks to improved healthcare infrastructure.
Market Scope
Report Attributes |
Description |
Market Size in 2024 |
USD xx Billion |
Market
Forecast in 2034 |
USD xx Billion |
CAGR % 2024-2034 |
xx% |
Base
Year |
2023 |
Historic Data |
2016-2022 |
Forecast
Period |
2024-2034 |
Report USP
|
Production,
Consumption, company share, company heatmap, company production capacity,
growth factors and more |
Segments
Covered |
by
Therapeutic Applications, by Dosage Forms, by Distribution Channels and By
Region |
Regional Scope |
North America,
Europe, APAC, South America and Middle East and Africa |
Country
Scope |
U.S.; Canada;
U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia;
China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico;
Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria |
Panitumumab Industry: Dynamics & Restrains
Market opportunity:
We Market
Research: Panitumumab Dashboard
Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.
Panitumumab Segmentation
Market- By Therapeutic Applications Analysis
By Therapeutic Applications, the Panitumumab Market is Categories into Colorectal Cancer, Others. The Colorectal Cancer segment accounts for the largest share of around 92% in 2024.
The primary driver for Panitumumab in
colorectal cancer treatment is the increasing global incidence of colorectal
cancer, coupled with the drug's effectiveness as a targeted therapy, improving
patient outcomes and survival rates by inhibiting cancer cell growth and
proliferation.
The
following segments are part of an in-depth analysis of the global Panitumumab
market:
Market Segments |
|
by
Dosage Forms |
·
Injectable ·
Others |
by
Distribution Channels |
·
Hospitals ·
Specialty Clinics ·
Pharmacies ·
Others |
Panitumumab Industry: Regional Analysis
North America Market Forecast
North America dominates the Panitumumab Market with the highest revenue generating market with share of more than 48%. The high incidence of colorectal cancer and advanced healthcare infrastructure are primary drivers of Panitumumab market growth. Additionally, substantial healthcare expenditure and the presence of major pharmaceutical companies foster a supportive environment for the adoption of targeted therapies, improving patient outcomes and expanding market potential.